Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymosin-alpha-1

Thymalfasin, Zadaxin, Thymosin α1

Quick Stats
Studies 759
Trials 63
Score 1
2009 pubmed

Evidence-based review of clinical studies on trauma.

Key Findings

  • Trauma research can’t use randomized groups that include “no trauma” due to ethics
  • Studies use preclinical models, case series, and post‑injury treatment trials
  • Thymosin‑alpha‑1 is mentioned as a treatment studied after dental trauma, but no specific outcomes are reported

Practical Outcomes

  • There’s no actionable protocol or dosage recommendation for thymosin‑alpha‑1 from this abstract. Biohackers should treat this as background information only and wait for concrete clinical data before considering it for longevity or performance use.

Summary

The abstract explains that studying trauma, including with thymosin‑alpha‑1, is tricky because you can’t ethically assign people to get injured, so researchers rely on animal work, case reports, and trials that test treatments after the injury happens. It doesn’t give any clear data on how thymosin‑alpha‑1 works, how much to use, or any proven benefits for health‑hacking goals.

Abstract

Clinical studies on trauma represent an important example of the ethical limitations of clinical research because patients cannot be randomized to "trauma" and "no trauma" groups. Instead, this important area of research includes preclinical studies, permitting more comprehensive experimental designs, case series/retrospective studies, and randomized studies in which the intervention focuses on treatment delivered after occurrence of dental trauma.

Study Information

Provider

pubmed

Year

2009

DOI

10.1016/j.joen.2009.05.011